Stay up to date with the latest Mycovia news, press releases, and more. If you have any questions or comments regarding media inquiries, please reach out to [email protected].

08/01/2024

Mycovia Pharmaceuticals Announces Presentation of Results from Three Safety Studies Evaluating VIVJOA® (oteseconazole) in Subjects with Renal or Hepatic Impairment, and the Impact on QT Prolongation at the 2024 IDSOG Annual Meeting

Download PDF

03/26/2024

Mycovia Pharmaceuticals, Inc. Announces AllianceRx Walgreens Pharmacy and Walgreens Community-based Specialty Pharmacies as Exclusive Distributor of VIVJOA®

Download PDF

02/07/2024

Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd’s Commercial Launch of VIVJOA® (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China

Download PDF

01/31/2024

Mycovia Pharmaceuticals, Inc. Announces Publication of Partner Jiangsu Hengrui Pharmaceuticals’ Phase 3 Clinical Study Evaluating the Efficacy and Safety of VIVJOA® (Oteseconazole) Versus Fluconazole in Women with Vulvovaginal Candidiasis (VVC) in the Journal Antimicrobial Agents and Chemotherapy

Download PDF

08/21/2023

Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd’s Approval of Oteseconazole Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China

Download PDF
Transforming healthcare together Careers at Mycovia
Working together to transform healthcare Contact Us